Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 4, 2014
April 15, 2020
7021cd9e-7798-464d-9e2b-7182acf180d8
Related Documents
Labeling for Biosimilar and Interchangeable Biosimilar Products
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry
Guidance DocumentJuly 6, 2018Center for Drug Evaluation and Research
Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators
Guidance DocumentMay 15, 2015Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.